Therefore, the current study's goal was to evaluate tetrandrine's therapeutic potential in a rat atherosclerosis model by modifying the miR-34a and Wnt5a/Ror2/NF-κB cue. The gene discussed is WNT5A; the disease is atherosclerosis.